AP2002002674A0 - Clear Aqueous Anaesthetic composition. - Google Patents
Clear Aqueous Anaesthetic composition.Info
- Publication number
- AP2002002674A0 AP2002002674A0 APAP/P/2002/002674A AP2002002674A AP2002002674A0 AP 2002002674 A0 AP2002002674 A0 AP 2002002674A0 AP 2002002674 A AP2002002674 A AP 2002002674A AP 2002002674 A0 AP2002002674 A0 AP 2002002674A0
- Authority
- AP
- ARIPO
- Prior art keywords
- clear aqueous
- propofol
- compositions
- composition
- cyclodcxtrin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- 230000003444 anaesthetic effect Effects 0.000 title 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 abstract 3
- 229960004134 propofol Drugs 0.000 abstract 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 abstract 1
- 229940124326 anaesthetic agent Drugs 0.000 abstract 1
- 239000003193 general anesthetic agent Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Anesthesiology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN573MU2000 IN187686B (en:Method) | 2000-06-21 | 2000-06-21 | |
| PCT/IN2000/000124 WO2001097796A1 (en) | 2000-06-21 | 2000-12-14 | Clear aqueous anaesthetic composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AP2002002674A0 true AP2002002674A0 (en) | 2002-12-31 |
Family
ID=11097257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/2002/002674A AP2002002674A0 (en) | 2000-06-21 | 2000-12-14 | Clear Aqueous Anaesthetic composition. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US7138387B2 (en:Method) |
| EP (1) | EP1299095B1 (en:Method) |
| JP (1) | JP4907833B2 (en:Method) |
| KR (1) | KR100810066B1 (en:Method) |
| CN (1) | CN1254237C (en:Method) |
| AP (1) | AP2002002674A0 (en:Method) |
| AT (1) | ATE267592T1 (en:Method) |
| AU (2) | AU3597201A (en:Method) |
| BG (1) | BG107463A (en:Method) |
| BR (1) | BR0017268A (en:Method) |
| CA (1) | CA2414064C (en:Method) |
| DE (1) | DE60011149T2 (en:Method) |
| DK (1) | DK1299095T3 (en:Method) |
| EA (1) | EA005589B1 (en:Method) |
| ES (1) | ES2222271T3 (en:Method) |
| HU (1) | HUP0301646A3 (en:Method) |
| IL (1) | IL153387A0 (en:Method) |
| IN (1) | IN187686B (en:Method) |
| MX (1) | MXPA02012611A (en:Method) |
| NO (1) | NO20025999D0 (en:Method) |
| NZ (1) | NZ523643A (en:Method) |
| PL (1) | PL359624A1 (en:Method) |
| PT (1) | PT1299095E (en:Method) |
| WO (1) | WO2001097796A1 (en:Method) |
| YU (1) | YU2703A (en:Method) |
| ZA (1) | ZA200300336B (en:Method) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN188917B (en:Method) * | 2000-12-07 | 2002-11-23 | Bharat Surums & Vaccines Ltd | |
| US7034013B2 (en) | 2001-03-20 | 2006-04-25 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
| US20050042280A1 (en) * | 2001-12-28 | 2005-02-24 | Rogers Tracey L. | Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol |
| BR0307518A (pt) * | 2002-02-01 | 2004-12-28 | Shimoda Biotech Pty Ltd | Composição farmacêutica |
| US7550155B2 (en) | 2002-07-29 | 2009-06-23 | Transform Pharmaceuticals Inc. | Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses |
| AU2003261274C1 (en) * | 2002-07-29 | 2009-02-12 | Transform Pharmaceuticals, Inc. | Aqueous 2,6-diisopropylphenol pharmaceutical compositions |
| EP3470084A1 (en) * | 2002-12-09 | 2019-04-17 | Abraxis BioScience, LLC | Compositions and methods of delivery of pharmacological agents |
| KR20060130646A (ko) * | 2004-01-14 | 2006-12-19 | 가부시키가이샤 오츠까 세이야꾸 고죠 | 프로포폴 함유 지방 유제 |
| EA200700440A1 (ru) * | 2004-09-13 | 2008-02-28 | Бхарат Сирумс Энд Вэксинс Лтд. | Композиции стабильных эмульсий для внутривенного введения, имеющие защитную эффективность |
| MX2008001981A (es) * | 2005-08-12 | 2008-03-25 | Bharat Serums & Vaccines Ltd | Composiciones anestesicas acuosas que comprenden propofol. |
| WO2007128866A2 (en) * | 2006-05-09 | 2007-11-15 | Novobion Oy | Novel chemical compositions |
| EP2269116A4 (en) * | 2008-03-11 | 2011-09-07 | 3M Innovative Properties Co | PHOTOGRAPHIC MASKS HAVING PROTECTIVE LAYER |
| WO2010148288A2 (en) * | 2009-06-19 | 2010-12-23 | Lyotropic Therapeutics, Inc. | Pharmaceutical formulations with low aqueous levels of free unbound drug |
| EP2456823A4 (en) | 2009-07-21 | 2012-12-26 | 3M Innovative Properties Co | CURABLE COMPOSITION, METHOD FOR COATING A PHOTO TOOL, AND COATED PHOTO TOOL |
| KR101781659B1 (ko) | 2009-09-16 | 2017-09-25 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | 플루오르화된 코팅 및 그로 제조된 포토툴 |
| KR101768237B1 (ko) | 2009-09-16 | 2017-08-14 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | 플루오르화된 코팅 및 그로 제조된 포토툴 |
| US8268067B2 (en) * | 2009-10-06 | 2012-09-18 | 3M Innovative Properties Company | Perfluoropolyether coating composition for hard surfaces |
| EP2345427A1 (de) * | 2010-01-14 | 2011-07-20 | SapioTec GmbH | Flurankomplex |
| DK2484350T3 (en) * | 2011-02-04 | 2016-08-01 | Norbert Univ -Prof Dr Med Roewer | A pharmaceutical composition containing a complex of a cyclodextrin with a propofolsalt |
| AU2013273764B2 (en) * | 2011-11-29 | 2016-05-05 | Zoetis Services Llc | Pharmaceutical compositions |
| WO2013078500A1 (en) * | 2011-11-29 | 2013-06-06 | Jurox Pty Ltd | Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug |
| CN103263404B (zh) * | 2012-04-28 | 2017-12-01 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 一种复合麻醉药物 |
| SG10201608148TA (en) | 2012-08-21 | 2016-11-29 | Sage Therapeutics Inc | Methods Of Treating Epilepsy Or Status Epilepticus |
| US10646439B2 (en) * | 2016-01-29 | 2020-05-12 | Cuda Anesthetics, Llc | Aqueous pharmaceutical formulation comprising propofol |
| FR3117337B1 (fr) | 2020-12-10 | 2023-04-28 | Centre Hospitalier Univ De Lille | Composition pharmaceutique contenant du propofol, une cyclodextrine ou un dérivé de cyclodextrine et un sel pharmaceuticalement acceptable |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA962214B (en) * | 1995-04-10 | 1996-10-07 | Farmarc Nederland Bv | Pharmaceutical composition |
-
2000
- 2000-06-21 IN IN573MU2000 patent/IN187686B/en unknown
- 2000-12-14 AU AU3597201A patent/AU3597201A/xx active Pending
- 2000-12-14 CN CNB008198292A patent/CN1254237C/zh not_active Expired - Fee Related
- 2000-12-14 EP EP00991825A patent/EP1299095B1/en not_active Expired - Lifetime
- 2000-12-14 WO PCT/IN2000/000124 patent/WO2001097796A1/en not_active Ceased
- 2000-12-14 JP JP2002503273A patent/JP4907833B2/ja not_active Expired - Fee Related
- 2000-12-14 AP APAP/P/2002/002674A patent/AP2002002674A0/en unknown
- 2000-12-14 ES ES00991825T patent/ES2222271T3/es not_active Expired - Lifetime
- 2000-12-14 PT PT00991825T patent/PT1299095E/pt unknown
- 2000-12-14 IL IL15338700A patent/IL153387A0/xx not_active IP Right Cessation
- 2000-12-14 KR KR1020027017362A patent/KR100810066B1/ko not_active Expired - Fee Related
- 2000-12-14 DE DE60011149T patent/DE60011149T2/de not_active Expired - Lifetime
- 2000-12-14 PL PL00359624A patent/PL359624A1/xx unknown
- 2000-12-14 NZ NZ523643A patent/NZ523643A/en not_active IP Right Cessation
- 2000-12-14 MX MXPA02012611A patent/MXPA02012611A/es active IP Right Grant
- 2000-12-14 DK DK00991825T patent/DK1299095T3/da active
- 2000-12-14 HU HU0301646A patent/HUP0301646A3/hu unknown
- 2000-12-14 CA CA2414064A patent/CA2414064C/en not_active Expired - Fee Related
- 2000-12-14 YU YU2703A patent/YU2703A/sh unknown
- 2000-12-14 EA EA200300047A patent/EA005589B1/ru not_active IP Right Cessation
- 2000-12-14 BR BR0017268-5A patent/BR0017268A/pt not_active Application Discontinuation
- 2000-12-14 AU AU2001235972A patent/AU2001235972B2/en not_active Ceased
- 2000-12-14 AT AT00991825T patent/ATE267592T1/de active
- 2000-12-14 US US10/296,765 patent/US7138387B2/en not_active Expired - Lifetime
-
2002
- 2002-12-13 NO NO20025999A patent/NO20025999D0/no not_active Application Discontinuation
-
2003
- 2003-01-13 ZA ZA200300336A patent/ZA200300336B/en unknown
- 2003-01-16 BG BG107463A patent/BG107463A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP2002002674A0 (en) | Clear Aqueous Anaesthetic composition. | |
| BR0008590A (pt) | Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto | |
| GEP20053473B (en) | High Potency Dihydroergotamine Compositions | |
| TWI256891B (en) | 17alpha-alkyl-17beta-oxy-estratrienes and intermediate products for their production, use of the 17alpha-alkyl-17beta-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations | |
| SG146648A1 (en) | Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation | |
| MXPA02012855A (es) | Compuestos y composiciones para suministrar agentes activos. | |
| DK1157037T3 (da) | GCSF-konjugater | |
| BR0111206A (pt) | Derivados de arilmetilamina para uso como inibidores de triptase | |
| HUT75513A (en) | Taxane class derivative based pharmaceutical compositions and their preparation | |
| MXPA04004837A (es) | Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1. | |
| PL370111A1 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
| UA103758C2 (ru) | Конъюгаты олигомеров инсулина, их композиции и применение | |
| AU2003273413A1 (en) | Pharmaceutically active oligosaccharide conjugates | |
| MEP36608A (en) | Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics | |
| BG103969A (en) | C-4"-substituted macrolide derivatives | |
| NZ524138A (en) | Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents | |
| GEP20033079B (en) | Pharmaceutical Compositions for Treatment of Diseases Caused by Estrogens Deficiency | |
| BR0109672A (pt) | Uso de zd6126 ou de um seu sal farmaceuticamente aceitável e um de: um agente antitumoral de plantina e um taxano, composição farmacêutica, produto de combinação, kit, e, método para a produção de um efeito de danificação vascular em um animal de sangue quente | |
| MX228228B (es) | Composiciones de propofol claras, estables. | |
| IL163608A (en) | Sulfonanilides are conserved in their amino / amino acids and derivatives, their process, their pharmaceutical preparations, and their conjugated antibodies and their use in the preparation of drugs for the treatment of culture disorders | |
| ES2105923B1 (es) | Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv). | |
| CA2344686A1 (en) | High purity composition comprising (7.alpha.,17.alpha.)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one | |
| BE2016C017I2 (en:Method) | ||
| ES2170649B1 (es) | Uso de la cdp-colina en el tratamiento de la abstinencia alcoholica. | |
| MXPA04002099A (es) | Composiciones medicinales para neuropatia diabetica. |